To maintain the activity of IL2 and abrogate its toxicity, a new form of IL2 immunotherapy through the delivery of a cell membrane-bound mouse IL2 by tumor-targeted oncolytic vaccinia was investigated. Here, IL2 is linked to neoplasm.